Golinelli, Giulia
Grisendi, Giulia
Prapa, Malvina
Bestagno, Marco
Spano, Carlotta
Rossignoli, Filippo http://orcid.org/0000-0001-7838-1542
Bambi, Franco http://orcid.org/0000-0002-1945-8324
Sardi, Iacopo
Cellini, Monica
Horwitz, Edwin M.
Feletti, Alberto
Pavesi, Giacomo
Dominici, Massimo http://orcid.org/0000-0002-4007-1503
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (12755, 17326, 12755, 17326, 12755, 17326, 12755, 17326)
Associazione Sostegno Ematologia e Oncologia Pediatrica
Article History
Received: 23 August 2018
Revised: 6 October 2018
Accepted: 20 October 2018
First Online: 22 November 2018
Compliance with ethical standards
:
: MD is founder of Rigenerand srl, a University start-up company developing gene therapy approaches for cancer. MD is also member of the Board of Directors of Rigenerand srl. MD interests are managed by the University of Modena and Reggio Emilia in accordance with their conflict of interest policies. CS and G Grisendi are currently employed by Rigenerand srl. The other authors declare that they have no conflict of interests.